Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Letters to the Editor
Editorial
,
Letters to the Editor
JHOP Editorial Board Member, Readers, and Author Interact - Optimizing the Administration of Daratumumab
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Dr Soefje is Director, Pharmacy Cancer Care, Mayo Clinic, Rochester, MN.
Read More
Letters to the Editor
,
Editorial
JHOP Editorial Board Member, Readers, and Author Interact - Comment on Kye et al (April 2023), Authors’ Response
Read More
Letters to the Editor
Anticoagulant Use in Patients with Ibrutinib-Related Atrial Fibrillation
Read More
Letters to the Editor
Impact of Pharmacists’ Intervention in Altering Prescribing Patterns for the Treatment of VTE in Patients with Cancer
Read More
Results 1 - 4 of 4